Profile data is unavailable for this security.
About the company
Aspen Pharmacare Holdings Limited is a South Africa-based global specialty and branded multinational pharmaceutical company. The Company focuses on marketing and manufacturing a range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. Its segments include Prescription, Over the counter (OTC), Injectables, Active Pharmaceutical Ingredients (API), Finished Dose Form (FDF) and Heparin. It offers sterile products in injectable form primarily administered in hospitals and also those prescribed and administered by either physicians or in a retail pharmacy environment. Its key brands include Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon and Xylocaine (Injectables). Its OTC segment includes products that do not require prescriptions and are primarily sold in the retail pharmacy and fast-moving consumer goods sectors. Its Prescription segment includes products which generally require a prescription from a healthcare professional.
- Revenue in ZAR (TTM)43.36bn
- Net income in ZAR-1.08bn
- Incorporated1985
- Employees9.13k
- LocationAspen Pharmacare Holdings LtdAspen Place, 9 Rydall Vale ParkDouglas Saunders Drive ,La Lucia RidgeLA LUCIA South AfricaZAF
- Phone+27 315808600
- Fax+27 112396111
- Websitehttps://www.aspenpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gland Pharma Ltd | 10.76bn | 1.49bn | 52.45bn | 4.35k | 35.17 | -- | 23.68 | 4.87 | 51.42 | 51.42 | 371.01 | -- | -- | -- | -- | 14,049,110.00 | -- | 10.77 | -- | 11.98 | 65.00 | 57.00 | 13.86 | 19.59 | -- | 34.31 | -- | 14.03 | -0.8512 | 16.36 | -9.57 | -2.00 | 15.15 | -- |
| Bloomage Biotechnology Corp Ltd | 10.78bn | 149.49m | 52.65bn | 4.44k | 338.86 | 3.20 | -- | 4.88 | 0.1394 | 0.1394 | 9.59 | 14.76 | 0.5431 | 1.12 | 8.61 | 1,048,475.00 | 0.719 | 8.43 | 0.827 | 9.97 | 70.71 | 75.45 | 1.32 | 12.34 | 1.42 | 40.02 | 0.0317 | 30.32 | -11.61 | 23.29 | -70.59 | -21.53 | 9.89 | -21.54 |
| Liquidia Corp | 1.11bn | -1.95bn | 53.11bn | 157.00 | -- | 150.39 | -- | 48.01 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
| PegBio Co Ltd | -204.49bn | -204.49bn | 53.26bn | 58.00 | -- | 89.02 | -- | -- | -- | -- | -- | 0.7481 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.07 | -- | 0.2439 | -- | -- | -- | -1.49 | -- | -- | -- |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 20.15bn | 1.08bn | 54.41bn | 9.07k | 48.25 | 2.47 | -- | 2.70 | 0.3256 | 0.3256 | 6.00 | 6.35 | 0.4279 | 0.9611 | 3.17 | 960,689.80 | 2.18 | 5.67 | 3.15 | 7.93 | 59.76 | 60.79 | 5.10 | 11.66 | 0.7399 | 8.95 | 0.4519 | 31.74 | 14.91 | 12.12 | 34.74 | 14.46 | 18.47 | 6.58 |
| Grand Pharmaceutical Group Ltd | 23.93bn | 4.25bn | 54.80bn | 12.44k | 12.70 | 1.54 | 10.34 | 2.29 | 0.5943 | 0.5943 | 3.35 | 4.90 | 0.4557 | 3.66 | 3.88 | 976,472.80 | 7.99 | 10.40 | 10.81 | 14.24 | 57.64 | 61.04 | 17.53 | 22.80 | 0.9872 | -- | 0.2107 | 29.12 | 10.59 | 12.06 | 31.30 | 16.49 | 0.7398 | 22.05 |
| Aspen Pharmacare Holdings Ltd | 43.36bn | -1.08bn | 54.89bn | 9.13k | -- | 0.6433 | 54.56 | 1.27 | -2.44 | -2.44 | 97.66 | 191.19 | 0.3154 | 1.35 | 3.34 | 4,750,548.00 | -0.7878 | 3.15 | -0.929 | 3.94 | 44.11 | 45.63 | -2.50 | 9.67 | 1.18 | 5.04 | 0.2985 | 33.78 | -3.00 | 5.20 | -124.59 | -- | 13.45 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 9.56bn | 574.03m | 54.96bn | 315.00 | 101.19 | 6.39 | 91.94 | 5.75 | 0.4484 | 0.4484 | 7.81 | 7.10 | 0.9435 | 2.13 | 15.61 | 1,898,327.00 | 5.67 | -8.31 | 6.85 | -9.52 | 87.52 | -- | 6.01 | -17.33 | 3.51 | -- | 0.00 | -- | 56.60 | -- | -406.68 | -- | -38.71 | -- |
| Almirall SA | 20.43bn | 798.05m | 55.00bn | 2.08k | 68.74 | 1.97 | 41.22 | 2.69 | 0.1967 | 0.1967 | 5.00 | 6.87 | 0.4626 | 1.35 | 7.02 | 532,457.60 | 1.81 | 0.0824 | 2.06 | 0.0971 | 77.61 | 78.13 | 3.91 | 0.2141 | 1.93 | -- | 0.186 | -- | 10.20 | 2.88 | 126.37 | -37.44 | 3.63 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 7.38bn | 1.33bn | 55.92bn | 5.52k | 41.71 | -- | 34.06 | 7.58 | 47.44 | 47.44 | 263.86 | -- | -- | -- | -- | 7,600,215.00 | -- | 15.91 | -- | 19.18 | 67.95 | 62.00 | 17.98 | 16.36 | -- | 164.76 | -- | 33.55 | 12.45 | 17.16 | 19.35 | 19.53 | 10.52 | 23.03 |
| Camurus AB | 4.05bn | 1.31bn | 56.20bn | 285.00 | 42.89 | 7.43 | 41.37 | 13.89 | 12.25 | 12.25 | 37.75 | 70.73 | 0.5332 | 1.24 | 5.36 | 7,948,695.00 | 17.31 | 14.26 | 19.13 | 16.65 | 93.11 | 91.95 | 32.47 | 21.07 | 11.78 | -- | 0.0244 | 0.00 | 21.30 | 46.47 | 71.70 | -- | 110.82 | -- |
| Virbac SA | 27.14bn | 2.52bn | 57.13bn | 5.62k | 22.64 | 2.83 | 15.49 | 2.11 | 15.88 | 15.88 | 171.01 | 127.13 | 0.7934 | 1.19 | 6.42 | 254,932.90 | 7.36 | 9.61 | 10.03 | 13.56 | 66.54 | 65.89 | 9.28 | 10.96 | 1.04 | 16.57 | 0.2337 | 8.06 | 12.07 | 8.29 | 19.78 | 23.03 | 28.46 | -- |
| Santen Pharmaceutical Co Ltd | 29.98bn | 3.19bn | 57.45bn | 3.85k | 18.61 | 1.94 | 11.33 | 1.92 | 92.03 | 92.03 | 865.27 | 880.97 | 0.7205 | 2.26 | 4.18 | 74,823,070.00 | 7.63 | 3.94 | 9.43 | 4.93 | 56.89 | 58.97 | 10.59 | 6.01 | 1.89 | -- | 0.1757 | 71.86 | -0.6494 | 4.43 | 36.09 | 8.94 | 3.61 | 5.92 |
Data as of Feb 17 2026. Currency figures normalised to Aspen Pharmacare Holdings Ltd's reporting currency: South African Rand ZAR
46.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Public Investment Corporation (SOC) Ltd.as of 30 Jun 2025 | 90.04m | 20.18% |
| Coronation Asset Management (Pty) Ltd.as of 29 Aug 2025 | 53.01m | 11.88% |
| Allan Gray (Pty) Ltd.as of 30 Jun 2025 | 20.09m | 4.50% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 13.93m | 3.12% |
| Foord Asset Management Pty Ltd.as of 30 Jun 2025 | 7.71m | 1.73% |
| Old Mutual Life Assurance Co. (South Africa) Ltd.as of 30 Jun 2025 | 6.02m | 1.35% |
| Sanlam Investment Management (Pty) Ltd.as of 30 Jun 2025 | 5.88m | 1.32% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 4.56m | 1.02% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 3.67m | 0.82% |
| Centaur Asset Management Pty Ltd.as of 31 Dec 2025 | 3.08m | 0.69% |
More ▼
Data from 31 Dec 2024 - 03 Feb 2026Source: FactSet Research Systems Inc.
